Latest revision as of 14:24, 21 May 2026

Mesothelioma Treatment Options and Costs: 4 FDA-Approved Therapies, 53+ Active Clinical Trials, $100,000-$400,000 Annual Expenses, and Financial Recovery Strategies (2026)

Treatment Cost Quick Facts
	What mesothelioma patients face financially
First-Year Costs	$100,000 - $400,000+
Immunotherapy	$150,000-$256,000/year
Surgery (P/D)	$54,000 procedure
Chemo Course	$38,779-$87,741
Avg. Settlement	$1-$1.4 Million
	🛡️ Get Compensation Help →

Executive Summary

Mesothelioma treatment costs average $11,000-$12,000 monthly, with first-year expenses typically ranging from $100,000 to over $400,000 depending on treatment selection and complications. The treatment landscape has transformed since 2020, with immunotherapy combinations now achieving a median survival of approximately 18.1 months compared with 12-14 months for chemotherapy alone, and a 5-year overall survival rate of 14% with first-line nivolumab plus ipilimumab in the CheckMate 743 5-year follow-up. Four FDA-approved treatment pathways exist as of 2026: traditional chemotherapy, immunotherapy combinations, surgical resection, and radiation therapy, with multimodal approaches combining these modalities offering the best outcomes for eligible patients. There is no cure for mesothelioma — current treatments extend survival and improve quality of life rather than eliminate the disease — but the 53+ actively recruiting U.S. clinical trials enrolling patients in 2026 represent the largest research pipeline in the disease's history. These escalating treatment costs underscore the critical importance of pursuing mesothelioma compensation through multiple channels including asbestos trust funds, VA benefits, and legal claims against responsible manufacturers.

Why This Matters

Understanding treatment costs directly impacts case valuation and settlement negotiations. Families facing mesothelioma diagnosis must document every expense from diagnosis through ongoing care, as these costs form a substantial portion of legal damages. The combination of extended survival with new therapies and escalating treatment expenses means comprehensive financial planning has never been more important for ensuring patients receive optimal care while families pursue full compensation for asbestos exposure injuries.

Key Facts Box: 2026 Mesothelioma Treatment Statistics

Essential Treatment and Cost Information
Monthly Treatment Costs	$11,000-$12,000 average across all modalities
Immunotherapy Annual Cost	$150,000-$256,000 for nivolumab plus ipilimumab
P/D Surgery Survival	21 months median with 2.2% 30-day mortality
CheckMate 743 Results	18.1 months survival, 23% alive at 3 years
September 2024 FDA Approval	Pembrolizumab + chemotherapy (52% response rate)
Active Clinical Trials	53+ trials recruiting in U.S. as of 2026 (per active trials registry)
Medicare Out-of-Pocket	~$8,000 annual maximum
Average Legal Settlement	$1-$1.4 million (trust funds, lawsuits combined)

Is There a Cure for Mesothelioma?

No. There is currently no cure for mesothelioma. Available treatments — chemotherapy, immunotherapy, surgery, and radiation — extend survival and improve quality of life, but do not eliminate the disease. Median overall survival with modern multimodal therapy ranges from approximately 12 months for chemotherapy alone to a median of 18.1 months with first-line nivolumab plus ipilimumab (the CheckMate 743 regimen), with a 5-year overall survival rate of 14% in the most recent follow-up.^[1]^[2] A subset of patients — typically those with epithelioid histology, early-stage disease, and good performance status — achieve long-term survival exceeding 5 years, particularly with aggressive multimodal therapy at high-volume centers, but these outcomes remain the exception rather than the rule.^[3]

The 53+ actively recruiting U.S. clinical trials in 2026 — including mesothelin-targeted CAR-T cell therapy, BAP1-stratified targeted approaches, and novel immunotherapy combinations — represent the largest research pipeline in the disease's history and offer the best current pathway toward what could eventually become curative therapy.^[4] Until such advances mature, treatment goals for mesothelioma patients focus on three measurable endpoints: (1) extending overall survival, (2) controlling symptoms and complications such as pleural effusion and dyspnea, and (3) preserving quality of life and functional status through palliative care integration. Patients facing a mesothelioma diagnosis should consult both an experienced mesothelioma specialist and a board-certified mesothelioma attorney to evaluate clinical trial eligibility and ensure financial recovery options are pursued in parallel with treatment.

What Are the Current FDA-Approved Treatment Options for Mesothelioma?

Modern mesothelioma treatment has evolved significantly, with four primary modalities now available to patients. The selection of treatment depends on disease stage, histologic subtype, patient performance status, and treatment goals.

ℹ️ Treatment Selection Guidance: Epithelioid histology patients typically benefit from surgical approaches combined with chemotherapy, while non-epithelioid cases (sarcomatoid, biphasic) show superior responses to immunotherapy combinations. Treatment decisions should involve multidisciplinary teams at specialized mesothelioma centers.

The four FDA-approved treatment categories include surgical resection, platinum-based chemotherapy, checkpoint inhibitor immunotherapy, and radiation therapy. Most patients with favorable performance status receive multimodal therapy combining two or more of these approaches in carefully sequenced protocols.

According to Paul Danziger of Danziger & De Llano, "The evolution of mesothelioma treatment over the past five years has been remarkable. We're seeing patients who would have had limited options just a decade ago now accessing multiple effective therapies. Understanding these options helps families plan both medically and financially for what lies ahead."

How Has Surgery for Mesothelioma Changed?

The surgical landscape has shifted decisively toward lung-sparing approaches based on compelling 2024 systematic review data analyzing 18,124 citations. Mesothelioma surgery now favors pleurectomy/decortication over the more aggressive extrapleural pneumonectomy for most patients.

What Is Pleurectomy/Decortication (P/D)?

Pleurectomy/decortication is defined as a lung-sparing surgical procedure that removes the diseased pleural lining while preserving the lung itself. The procedure involves removing both parietal and visceral pleura, potentially including diaphragmatic or pericardial resection when needed (extended P/D).

Surgical Approach	30-Day Mortality	Median Survival	Hospital Stay	Procedure Cost
Pleurectomy/Decortication (P/D)	2.2%	21 months	5-7 days	$53,993
Extrapleural Pneumonectomy (EPP)	6%	18.1 months	7-14 days	$62,408

The NCCN 2024 guidelines recommend surgery only for stage I disease limited to pleura without lymph node involvement, with P/D preferred due to its superior safety profile. According to research from major treatment centers, experienced surgical programs achieve perioperative mortality below 3% for P/D procedures.

✅ Surgical Advance: Some experienced centers report 0% mortality for P/D procedures. The shift from EPP to P/D represents a fundamental change in how surgeons approach mesothelioma, prioritizing quality of life alongside survival outcomes.

What Are the Total Surgical Costs?

Total first-year surgical costs extend well beyond the procedure itself. Patients should anticipate:

Pre-operative workup: $7,567 (including PET-CT, pulmonary function tests, cardiac evaluation)

Initial hospitalization: $24,901 average per episode

Post-operative care: $30,096 during the first month (40% complication rate for EPP, 20-25% for P/D)

Total first-year surgical pathway: $100,000-$150,000 for P/D; $150,000-$200,000 for EPP including rehabilitation

"The patterns we observe in surgical cases consistently show that patients treated at high-volume centers experience better outcomes," explains Rod De Llano. "This is why we encourage families to seek second opinions at specialized mesothelioma treatment centers before making surgical decisions."

What Chemotherapy Options Are Available for Mesothelioma?

Mesothelioma chemotherapy remains foundational to treatment, with the pemetrexed plus cisplatin combination established as the standard backbone since 2003.

What Is First-Line Chemotherapy?

First-line chemotherapy refers to the initial drug regimen used to treat mesothelioma, typically combining pemetrexed 500 mg/m² with cisplatin 75 mg/m² administered intravenously every 21 days for 4-6 cycles. This combination achieves response rates of 41.3% with median overall survival of 12.1 months.

⚠️ Critical Supportive Care: Patients must receive folic acid (350-1000 μg daily) and vitamin B12 (1000 μg intramuscularly every 9 weeks) starting 3 weeks before chemotherapy begins. These supplements prevent severe toxicity and must continue throughout treatment.

Chemotherapy Cost Breakdown:

Standard 6-cycle cisplatin/pemetrexed course: $38,779-$40,102

With bevacizumab addition: $87,741 plus $8,160 monthly maintenance

Second-line options (gemcitabine, vinorelbine): $20,000-$40,000

Administration and monitoring per cycle: $2,500-$6,000 beyond drug costs

The MAPS trial demonstrated that adding bevacizumab 15 mg/kg every 3 weeks extends median overall survival to 18.8 months versus 16.1 months (HR 0.77, p=0.0167), though this combination lacks FDA approval and requires insurance authorization as off-label use.

How Does Immunotherapy Work for Mesothelioma?

Immunotherapy for mesothelioma represents the most significant treatment advance since pemetrexed approval in 2003. These drugs work by removing the "brakes" on the immune system, allowing it to recognize and attack cancer cells.

What Are the FDA-Approved Immunotherapy Options?

Two immunotherapy combinations have received FDA approval for mesothelioma as of 2026, with a third (pembrolizumab + berahyaluronidase alfa, marketed as Keytruda Qlex) approved September 19, 2025 as a subcutaneous co-formulation of the existing pembrolizumab regimen:

1. Nivolumab Plus Ipilimumab (October 2020 Approval)

The CheckMate 743 trial established this combination as a breakthrough first-line option. Nivolumab blocks PD-1, while ipilimumab blocks CTLA-4, creating a two-pronged attack on cancer's immune evasion mechanisms.

CheckMate 743 Results
Median Overall Survival	18.1 months (vs 14.1 months chemotherapy)
3-Year Survival Rate	23% (vs 15% chemotherapy)
Response Rate	40%
Non-Epithelioid Response	HR 0.46 (exceptional benefit)
Annual Cost	$150,000-$256,000

2. Pembrolizumab Plus Chemotherapy (September 2024 Approval)

The KEYNOTE-483 trial supported the newest approval, demonstrating 52% overall response rate versus 29% with chemotherapy alone, with median overall survival of 17.3 months.^[5]

ℹ️ Histology Matters: Non-epithelioid mesothelioma (sarcomatoid and biphasic subtypes) shows remarkable responses to nivolumab plus ipilimumab, while epithelioid cases may benefit more from pembrolizumab plus chemotherapy. Treatment selection should consider histologic subtype.

What Are Immunotherapy Side Effects and Costs?

Immunotherapy activation of the immune system can cause it to attack normal tissues, creating unique immune-related adverse events:

Common events: Fatigue (35-40%), skin reactions (25-30%), diarrhea/colitis (20-25%), thyroid dysfunction (15-20%)

Severe events: 26% experience grade 3-4 events with combination therapy; 23% require treatment discontinuation

Fatal events: Approximately 1.3% of patients

Side effect management costs: $500-$1,000 monthly routine monitoring; $15,000-$30,000 for hospitalization if severe events occur

According to Michelle Whitman, Attorney at Danziger & De Llano, "We work closely with families to document all treatment-related expenses, including the substantial costs of managing immunotherapy side effects. These expenses are recoverable through legal compensation claims."

What Role Does Radiation Play in Mesothelioma Treatment?

Radiation therapy provides local control of mesothelioma, typically combined with surgery or used palliatively for symptom management. Modern techniques have dramatically improved precision while reducing toxicity.

What Is the IMPRINT Radiation Protocol?

The IMPRINT protocol represents the current standard for post-operative radiation, delivering 50.4 Gy in 28 fractions over 5.5 weeks using intensity-modulated radiation therapy (IMRT).

IMPRINT Clinical Outcomes:

Median overall survival: 23.7 months

2-year survival rate: 59%

Local control rate: 80% at 2 years

Cost for complete IMRT course: $17,000-$27,400 plus planning ($3,000-$5,000)

✅ Proton Therapy Advantage: Available at approximately 40 U.S. centers, proton therapy demonstrates 37% 2-year survival versus 26% with conventional radiation. The ongoing NRG-LU006 trial is comparing proton therapy to IMRT for definitive evidence. Cost: $50,000-$90,000.

What Are the Total Costs of Multimodal Treatment?

Multimodal therapy combining surgery, chemotherapy, and radiation achieves the best outcomes for eligible patients but creates substantial cumulative costs. Understanding these expenses is essential for legal case building.

Treatment Component	Cost Range	Typical Timeline
Neoadjuvant Chemotherapy	$25,000-$35,000	2-3 cycles pre-surgery
Surgery + Hospitalization	$100,000-$150,000	5-14 day stay
Adjuvant Chemotherapy	$25,000-$35,000	2-3 additional cycles
Radiation Therapy	$20,000-$35,000	5.5 weeks
Supportive Care	$20,000-$50,000	Ongoing
Total Trimodality	$250,000-$400,000	First Year

"The financial burden of mesothelioma treatment consistently exceeds what families anticipate," observes Paul Danziger. "We've helped families document costs that ultimately supported recoveries well exceeding $1 million when all damages—medical expenses, lost wages, pain and suffering—are properly calculated."

What Clinical Trials Are Available in 2026?

Clinical trials offer access to cutting-edge treatments not yet FDA approved, with 53+ actively recruiting trials in the United States as of 2026 — the largest pipeline in the disease's history. Current trial sponsors include Bristol-Myers Squibb (nivolumab combinations), Merck (pembrolizumab maintenance regimens, NCT04971226), AstraZeneca (durvalumab-based regimens), GSK (mesothelin-targeted antibody-drug conjugates), and academic consortia investigating mesothelin-targeted CAR-T cell therapies (NCT02414269, NCT04577326). Trials are stratified by histologic subtype (epithelioid vs. biphasic/sarcomatoid), prior treatment status (first-line vs. progression), and biomarker eligibility (BAP1, mesothelin expression, PD-L1).

What Are the Most Promising Current Trials?

CAR-T Cell Therapy: The TNhYP218 trial at the National Cancer Institute targets mesothelin-expressing tumors, with early results showing 20% significant tumor reduction and 83% 1-year survival in select patients.

First AI-Designed Drug: ISM6331, developed by Insilico Medicine, became the first AI-designed drug to enter mesothelioma clinical trials with the first patient dosed in January 2025 and active enrollment continuing through 2026.

Liquid Biopsy Breakthrough: Johns Hopkins' Phase 2 trial demonstrated that patients with undetectable circulating tumor DNA at cycle 3 had median progression-free survival of 19.84 versus 1.41 months—a 14-fold difference enabling real-time treatment monitoring.

⚠️ Trial Participation Gap: Despite 70+ available trials, only 8% of mesothelioma patients participate. Geographic concentration of expertise requires many patients to travel, though patient advocacy organizations provide free trial matching and travel support.

Trial Financial Structure:

Research costs (study drug, protocol-required tests): Covered by sponsor

Routine care costs: Covered by insurance (ACA mandate)

Travel and lodging: Patient responsibility (assistance programs available)

How Can Patients Afford Mesothelioma Treatment?

Multiple financial assistance pathways exist to help manage mesothelioma treatment costs. Understanding and accessing all available resources is essential for ensuring optimal care.

What Insurance Coverage Is Available?

Medicare (70% of mesothelioma patients):

Part A covers hospital stays and surgery

Part B covers chemotherapy and physician visits

Annual out-of-pocket maximum: approximately $8,000

Part D adds prescription coverage with variable copays

Private Insurance:

Out-of-pocket maximum: $6,000-$12,046 annually

Prior authorization typically required for newer therapies

Network restrictions may limit treatment center access

Appeals success rate: 44-60% for initially denied claims

ℹ️ Veterans Coverage: Veterans with service-related asbestos exposure qualify for complete VA healthcare coverage without copays or deductibles, plus disability compensation up to $3,737/month for mesothelioma.

What Pharmaceutical Assistance Programs Exist?

Bristol Myers Squibb Access Support (Nivolumab/Ipilimumab): Co-pay assistance up to $25,000 annually; free drug program for uninsured/underinsured meeting income requirements

Merck Helps (Pembrolizumab): Maximum $25 out-of-pocket through co-pay program; patient assistance for qualifying individuals

Eli Lilly Cares (Pemetrexed): Free medication program with income verification

What Legal Compensation Is Available?

Legal compensation provides crucial funding for treatment and family support:

Compensation Source	Typical Amount	Timeline
Asbestos Trust Funds	$30,000-$300,000+	90 days - 12 months
Lawsuit Settlements	$1-$1.4 million average	6-18 months
Trial Verdicts	$5-$11.4 million average	12-24 months
VA Disability	Up to $3,737/month	3-6 months

What Should Families Document for Legal Cases?

Comprehensive documentation of treatment costs directly impacts case valuation and settlement negotiations.

Required Documentation Checklist

📋 Medical Documentation:

All treatment bills (surgery, chemotherapy, immunotherapy, radiation)
Pharmacy receipts for all medications including supportive care
Transportation costs to treatment centers
Lodging expenses for out-of-town treatment
Medical equipment and home care costs

💰 Financial Impact Documentation:

Lost wages during treatment (patient and caregiver)
Reduced earning capacity due to disability
Insurance premium increases
Out-of-pocket maximums reached

📑 Quality of Life Documentation:

Physical therapy and rehabilitation records
Mental health treatment for patient and family
Home modification requirements
Caregiver time and services

"Thorough documentation from the beginning makes an enormous difference in case outcomes," explains David Foster, Client Advocate at Danziger & De Llano. "When my father was diagnosed, we didn't know what to keep track of. Now I help families understand that every receipt, every missed day of work, every expense matters when building a comprehensive claim."

Conclusion: Treatment and Compensation Go Hand in Hand

Modern mesothelioma treatment offers more hope than ever before, with optimal multimodal therapy now achieving survival of 23-24 months at experienced centers. However, this progress comes with substantial costs that can exceed $400,000 in the first year alone. Understanding both treatment options and financial recovery pathways ensures patients receive optimal care while families secure the compensation they deserve.

The integration of immunotherapy, refined surgical techniques, and precision radiation continues advancing outcomes. Simultaneously, asbestos trust funds holding over $30 billion, combined with legal claims against manufacturers and VA benefits for veterans, provide multiple avenues for financial recovery that can cover treatment costs and provide for families.

🛡️ Get Help Understanding Your Treatment Options and Compensation Rights

Free consultation • No upfront costs • Over $2 billion recovered

📞 Call (866) 222-9990

📚 Related Resources

Guide	What You'll Learn
Asbestos Trust Fund Guide	How to access $30+ billion in available compensation
Veterans Benefits Guide	VA claims, disability ratings, and healthcare access
Clinical Trial Guide	Finding and enrolling in cutting-edge treatment trials
Emerging Treatments	Latest research and breakthrough therapies

References

↑ CheckMate 743 5-year survival data (14% nivolumab + ipilimumab vs 6% chemotherapy alone) — first 5-year immunotherapy outcomes in pleural mesothelioma, integrated from Medical research library benchmark compilation.
↑ Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. Journal of Clinical Oncology. 2026 Mar 20. PMID 41734361.
↑ Bibby AC, Tsim S, Kanellakis N, Ball H, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. European Respiratory Review. 2016;25(142):472-486. PMID 27903668.
↑ "Mesothelioma Treatment Options in 2026: 56+ Clinical Trials, Immunotherapy & Survival Breakthroughs," MLNM Blog, January 2026.
↑ Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023 Dec 16;402(10419):2295-2306. PMID 37931632.

Additional Sources

Medical & Treatment Information:

Mesothelioma Treatment Overview - Mesothelioma.net
Mesothelioma Surgery Options - Mesothelioma.net
Chemotherapy for Mesothelioma - Mesothelioma.net
Immunotherapy Treatment Guide - Mesothelioma.net
Multimodal Therapy Approaches - Mesothelioma.net
Mesothelioma Treatment Centers Directory - Mesothelioma.net
Clinical Trials Guide - Mesothelioma.net
Costs of Mesothelioma Care - Mesothelioma.net
Best Mesothelioma Treatment Centers - MesotheliomaAttorney.com
Treatment Options Overview - MesotheliomaAttorney.com

Legal & Compensation Resources:

Mesothelioma Compensation Guide - Danziger & De Llano
Mesothelioma Settlements - Danziger & De Llano
Diagnosis and Legal Rights - Danziger & De Llano
Case Valuation Information - Danziger & De Llano
Veterans Benefits Guide - Danziger & De Llano
Mesothelioma Attorney Services - Danziger & De Llano
Asbestos Trust Fund Payouts - Danziger & De Llano
Compensation Overview - MesotheliomaAttorney.com

Research & News:

Surgery Outcomes Study - Mesothelioma Lawyer Center
FDA Approval News: Immunotherapy - Mesothelioma Lawyer Center
Mesothelioma Overview - Mesothelioma Lawyer Center
Cancer Vaccine Research - Mesothelioma Lawyer Center

Clinical Trial Data:

CheckMate 743 Trial - Nivolumab plus ipilimumab vs. chemotherapy (Baas et al., NEJM 2021; 4-year follow-up 2024)
KEYNOTE-483 Trial - Pembrolizumab plus pemetrexed/platinum, FDA approved September 17, 2024
MARS 2 Trial - Pleurectomy/decortication outcomes comparison
IMPRINT Protocol - Radiation therapy survival data

This comprehensive resource synthesizes peer-reviewed medical research, FDA approval documentation, clinical trial databases, and specialized legal and financial information from authoritative sources focused exclusively on mesothelioma treatment and asbestos-related disease compensation.

Clinical Trial Data: CheckMate 743 trial results (nivolumab plus ipilimumab), KEYNOTE-483 trial data (pembrolizumab plus chemotherapy), IMPRINT radiation protocol outcomes, and CAR-T cell therapy trial results from the National Cancer Institute.

Surgical Outcomes: 2024 systematic review analyzing 18,124 citations comparing pleurectomy/decortication to extrapleural pneumonectomy, NCCN 2024 clinical practice guidelines for malignant pleural mesothelioma.

Cost Analysis: Medicare reimbursement data, pharmaceutical pricing databases, and treatment center cost surveys from major mesothelioma treatment facilities.

Domain	Content Focus	Citations
dandell.com	Legal compensation, firm resources, settlements	11
mesothelioma.net	Medical treatment, clinical trials, patient resources	9
mesotheliomalawyercenter.org	Legal process, state-specific information, research news	4
mesotheliomaattorney.com	Treatment centers, compensation guides, types	3

Last Updated: May 2026. Medical information reflects FDA approvals through September 2025 (including Keytruda Qlex subcutaneous pembrolizumab co-formulation, BLA 761467, approved 2025-09-19), clinical trial status as of mid-2026 with 53+ actively recruiting U.S. trials, and current treatment cost estimates.

Disclaimer: This information is provided for educational purposes and does not constitute medical or legal advice. Treatment decisions should be made in consultation with qualified healthcare providers. Legal claims should be evaluated by experienced mesothelioma attorneys.

[lineage:e07212c08f9040fd8efdab37158bdcbb:f2a3b6690d71fa13-1] CheckMate 743 5-year survival data (14% nivolumab + ipilimumab vs 6% chemotherapy alone) — first 5-year immunotherapy outcomes in pleural mesothelioma, integrated from Medical research library benchmark compilation.

[checkmate743_5yr-2] Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. Journal of Clinical Oncology. 2026 Mar 20. PMID 41734361.

[ets_long_survivors-3] Bibby AC, Tsim S, Kanellakis N, Ball H, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. European Respiratory Review. 2016;25(142):472-486. PMID 27903668.

[ct_pipeline_2026-4] "Mesothelioma Treatment Options in 2026: 56+ Clinical Trials, Immunotherapy & Survival Breakthroughs," MLNM Blog, January 2026.

[keynote483_chu_2023-5] Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023 Dec 16;402(10419):2295-2306. PMID 37931632.

[1]

[2]

[3]

[4]

[5]